<DOC>
	<DOC>NCT00818519</DOC>
	<brief_summary>The purpose of this study is to evaluate the efficacy and safety of YAZ (drospirenone 3 mg / ethinylestradiol 20 Âµg) in comparison with placebo in female patients with moderate acne vulgaris over 6 treatment cycles.</brief_summary>
	<brief_title>GA YAZ ACNE in China Phase III</brief_title>
	<detailed_description />
	<mesh_term>Acne Vulgaris</mesh_term>
	<mesh_term>Drospirenone</mesh_term>
	<mesh_term>Contraceptives, Oral</mesh_term>
	<mesh_term>Ethinyl Estradiol</mesh_term>
	<mesh_term>Contraceptive Agents</mesh_term>
	<criteria>Women of age 1445 years &gt;1 year postmenarche with moderate acne vulgaris who have no known contraindications to combined oral contraceptives Otherwise healthy, except for the presence of moderate acne Smokers up to a maximum age of 30 (inclusive) at inclusion Pregnancy, lactation (less than three menstrual cycles since delivery, abortion, or lactation before start of treatment) Obesity (Body Mass Index &gt; 30 kg/m2) Hypersensitivity to any ingredient of the study drug Any disease or condition that may worsen under hormonal treatment</criteria>
	<gender>Female</gender>
	<minimum_age>14 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Moderate Acne Vulgaris</keyword>
	<keyword>Oral contraceptive</keyword>
	<keyword>Female</keyword>
</DOC>